German company begins testing possible vaccine

German company begins testing possible vaccine

BioNTech, which is working with U.S.-based Pfizer, said Wednesday that 12 participants of a clinical trial in Germany have received doses of the vaccine candidate BNT162 since April 23.

PTIUpdated: Wednesday, April 29, 2020, 10:39 PM IST
article-image
Scientists design a universal flu vaccine |

German pharmaceutical company BioNTech says it has begun testing a potential vaccine for the new coronavirus on volunteers.

BioNTech, which is working with U.S.-based Pfizer, said Wednesday that 12 participants of a clinical trial in Germany have received doses of the vaccine candidate BNT162 since April 23.

Numerous pharmaceutical companies are racing to deliver a vaccine for the virus that has caused a pandemic and led to more than 215,000 deaths worldwide and sickened at least three million people.

BioNTech said in a statement that in a next step, it will begin increasing the dose of BNT162 in a trial involving about 200 participants aged 18 to 55.

The company said it expects to receive regulatory approval to begin trials in the United States soon.

RECENT STORIES

Gold Tumbles ₹700 To ₹98,420/10g, Strong US Dollar & Fed Rate Worries Weigh

Gold Tumbles ₹700 To ₹98,420/10g, Strong US Dollar & Fed Rate Worries Weigh

Adani Enterprises ₹1,000 Crore Bond Issue Fully Subscribed, Investors Respond In Just Three Hours

Adani Enterprises ₹1,000 Crore Bond Issue Fully Subscribed, Investors Respond In Just Three Hours

Centre Tells Delhi High Court There's No Proposal To Issue ₹50 Coin Amid Plea Over Note's...

Centre Tells Delhi High Court There's No Proposal To Issue ₹50 Coin Amid Plea Over Note's...

Sensex, Nifty End Lower As IT & Oil Stocks Drag, Caution Builds Ahead Of Q1 Earnings Season

Sensex, Nifty End Lower As IT & Oil Stocks Drag, Caution Builds Ahead Of Q1 Earnings Season

Lupin, Zentiva Sign Global Pact For Certolizumab Pegol, Biosimilar To Be Commercialised Across Key...

Lupin, Zentiva Sign Global Pact For Certolizumab Pegol, Biosimilar To Be Commercialised Across Key...